NCT07209865View on ClinicalTrials.gov

68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
DRUG

68Ga-P16-093

Intravenous injection of Ga-P16-093 with a dosage of 111-148 MBq (3-4 mCi), followed by PET/CT or PET/MRI acquisition according to standard methods.

Trial Locations (1)

350005

RECRUITING

Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

First Affiliated Hospital of Fujian Medical University

OTHER